Cingulate begins dosing healthy subjects in Phase I trial of CTX-1301 to treat ADHD

US-based biopharmaceutical firm Cingulate Therapeutics has begun dosing healthy volunteers in the Phase I proof-of-concept trial of its product candidate CTX-1301.

Source: Drug Development Technology - May 31, 2017 Category: Pharmaceuticals Source Type: news